Podcasts about provenge

Available September 23, 2022Mark, Ray, and Scott discuss Pediatric Urology Coding and some of its nuances.  Also, they answer 2 pediatric urology coding questions:I think the great majority of us know that if a patient has been seen by me or one of the other providers in my practice within the past three years then he/she is considered an established patient. However, there is some controversy in my new practice. I left hospital employment and started a new private practice. Some information suggests that because this is a new practice with a new tax ID and a new Group NPI number that any patient seen is considered a new patient. I wish that were true but I think that is incorrect and even though this is an entirely new practice any patient seen by me or my nurse practitioner in the past three years should be considered an established patient for coding and billing. Which is correct? Thank you. I am needing clarification on if a patient can be seen by nurse/MA with no provider in office? Examples would be foley removals, phlebs, ua's, etc.  It was my understanding in the past we could not, but this issue came up recently when a doctor was ill and was not able to be in office.Thanks! Provenge billing: how many diagnoses? what about the Q codes - what's included?     Test Your Knowledge - What is your urology coding score?https://www.prsnetwork.com/uroscore Free Urology Coding Training For Residentshttps://www.prseducationfoundation.orgUrology Advanced Coding and Reimbursement Seminar  - Registration OpenLas Vegas, NV - December 2-3, 2022New Orleans, LA - January 27-28, 2023Register Now  Compliance PlansQuestions or need help, please send us an email: info@prsnetwork.com   Join the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.Click Here to Start Your Free Trial of AUACodingToday.com 

Dendreon, a pioneer in the cell therapy space through its commercial product Provenge, has relaunched itself as a contract development and manufacturing organization (CDMO). BioProcess Insider speaks with Maria Cho, the VP of Business Development and Corporate Strategy, about Dendreon's strategic growth efforts in the cellular immunotherapy space and how it is embracing its proven success in the field to support others.

In this episode, Darren Reinke chats with Phil Dana, Head of Human Resources at Dendreon. Phil shares how the lessons he learned in the military and in construction have benefited him in his HR career, the importance of cultivating purpose within your team and organization, and why he intentionally surrounds himself with those smarter than him. Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. Dendreon's flagship product, PROVENGE, was the first FDA-approved immunotherapy made from a patient's own immune cells. More than 40,000 men with advanced prostate cancer have been prescribed PROVENGE in the U.S. since 2010.  Show Notes:How Phil Ventured from the Navy Into Human Resources [1:06]How the Perception of HR Has Evolved Over Time [4:01]Why People and Culture Are Having Major Implications on Business Strategy [6:39]How Phil Creates a Thriving Culture in a Less Structured Environment [8:07]Why Creating an Authentic True North Serves as an Anchor for Your Company [10:38]The Key Steps Phil Takes to Create Individualized Purpose Within His Team [12:49]How You Can Create Your Own Sense of Purpose Regardless of Occupation [17:18]Why You Should Instill the Mindset of Lifelong Learning Within Your Team [20:19]Why Phil Enjoys Being the Dumbest Guy in the Room [22:53]The Crucial Skillsets Phil Looks for Before Making a Hiring Decision [26:32]How Phil Evaluates Peoples' Team Ability and the Importance of Hard Work [30:07] Links:Phil's LinkedIn: https://www.linkedin.com/in/militarytalent/Dendreon's LinkedIn: https://www.linkedin.com/company/dendreon/

March 26, 2021Mark, Ray, and Scott discuss a problem with United Health Care and payment delays for higher-priced claims (ie Provenge, Urolift).  What options do you have? What should you do?Share your payer stories with usEmail:  info@prsnetwork.comor on the free Q&A forum Urology Coding and Reimbursement Group.Take the 30 Day Urology Coding and Billing Challenge and learn what a coder, biller, admin and other non-QHPs should know and nothing more.Learn MoreJoin the discussion:Urology Coding and Reimbursement Group - Join for free and ask your questions, and share your wisdom.  Click Here to Start Your Free Trial of AUACodingToday.com 

Joel T Nowak from Cancer ABCs discusses with Dr. Rana McKay, Associate Professor of Medicine at the Moores Cancer Center at the University of California in San Diego, her recently published article that analysizes real world data that demonstrates that Provenge (sipuleucel-T), an immune therapy for castrate resistant metastatic prostate cancer (CRMPC), can reduce the risk of death over and above the newer hormone treatments that have been FDA approved . Dr, McKay evaluated a large medicare data base and determined that despite the addition of the many second generation hormone treatments like Zytiga, Xtandi and Nubequa Provenge continues to lower the risk of death for men with CRMPC. She also discussed research that she has ben involved in that has been evaluating survival risks for men with prostate cancer who get the COVID-19 virus. Support the show (https://www.cancerabcs.org/new-page-2/)

Philip Dana is the Head of HR for Dendreon. Dendreon is a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy. They are most notably known for their flagship product, PROVENGE which was the first FDA-approved immunotherapy made from a patient's own immune cells. This product is widely used for the treatment of prostate cancer. Phil has spent many years in HR and is an official member of the Forbes Human Resource Council. Thanks for listening and I hope you enjoy,Matt

We placed the VeteranCrowd Spotlight on Phil Dana, a Navy Veteran recognized as a thought-leader on Networking and Transition. A family tradition... Philip Dana grew up in a family steeped in Navy tradition. Twenty members of his family have served in the Navy or Marine Corps. Phil's grandfather was a Marine wounded at the base of Mt. Suribachi during the invasion of Iwo Jima. His father served in both Korea and Vietnam.  Dana grew up in the Philippines and other stations in the Pacific, and spent summers visiting his grandparents in the Pacific Northwest.  Upon graduation from high school, Dana enlisted in the Navy, and served four years as an air crewman. He applied and was accepted to the US Naval Academy at Annapolis. He attended NAPS and became a surface warfare officer upon graduation in 1998.  Dana has always sought entrepreneurial business opportunities, where process improvement and networking tools he has honed over the years could be best applied. Though he never envisioned a career in human resources, it became the natural fit. HIs military background and exposure to many in the special operations community led him to the Honor Foundation. The Honor Foundation a transition institute created exclusively for the U.S. Special Operations community. Phil served as a VP and “Chief of People Operations.  Hiring veterans is a “natural sidecar” you get with Phil Dana. He is passionate about Navy Football and is a lifelong Seattle Seahawks fan. And Phil Dana currently serves as the Head of Human Resources for Dendreon, a commercial stage biopharmaceutical company delivering personalized immunotherapy treatments for Stage IV metastasized cancers. Dendreon's PROVENGE reprograms the body's own immune cells to detect and attack cancer cells, with little impact to healthy tissue or cells. A networking thought leader Phil Dana is a recognised subject matter expert on hiring and networking, and he has sound advice for veterans on transitioning and the do's and don'ts when building a professional network. He is a beast on LinkedIn, having developed disciplines and strategies that have grown his network with leaders and influencers everywhere.   The Spotlight We placed Phil Dana in the Spotlight and he shared: Secrets of networking The art and science of using LinkedIn to become a thought leader Advice for transitioning veterans The proper way to build relationships, and what advice to ignore That 95% of opinions on Resumes are all wrong Veteran friendly business and avoiding patronizing The importance of mentors, sponsors, and candid feedback Executive coaches and the importance of reading  You can follow Philip Dana on Linkedin and learn about Dendreon Immunotherapy  https://www.linkedin.com/in/militarytalent/ And ask yourself, “Should I Join to the VeteranCrowd Network?” https://veterancrowdnetwork.com/contact/

Immunotherapy trains the patient’s own immune system to target and attack cancer cells. For men with prostate cancer immunotherapy can provide long-term efficacy with minimal side effects. This episode explores the innovations in immunotherapy including the use of off-label therapy and the promise of combination therapy. Don’t miss out on these new and exciting capabilitiesContinue reading

Dr. Tim Richardson talks with Joel Nowak talk about the real survival advantages that the immunotherapy known as Provenge (sipuleucel-T) offers to men, especially men who get the therapy while their PSA is low (Schellhammer data) and men with an African-American background. Along the way, they also talk about what is immunotherapy, how it works, how Provenge is actually administered, its side effects and who should get the treatment and where in their treatment schedule would it be best to get the treatment. Support the show (https://www.cancerabcs.org/new-page-2/)

Mark Hall was diagnosed with metastatic prostate cancer with a PSA of 4,400 and a Gleason Score of 8. Despite these terrible numbers he has been thriving the last four years with an undetectable PSA and a fantastic quality of life!Mark shares his journey, where under the guidance of Dr. Charles (Snuffy) Meyers he went through a heavy regime of hormone therapy treatments as well as the immunotherapy Provenge (sipuleucel-T). Mark has been experiencing a profound four year remission of his probate cancer. Mark attributes his remission to the Provenge treatment as well as Dr. Meyers guidance. The Cancer ABCs podcast program receives support from Genomic Health, which transforms treatment decisions in cancer by delivering clinically actionable diagnostics. Support the show (https://www.cancerabcs.org/new-page-2/)

Prostate Cancer Immunotherapy.  Dr. Neal Shore serves as Medical Director for the Carolina Urologic Research Center and is in practice at the Atlantic Urology Clinics in Myrtle Beach, South Carolina. Dr. Shore has conducted more than 250 clinical trials, focusing mainly on prostate and bladder disease, and serves on the boards of several academic and advocacy networks.  Dr. Shore is questioned by Joel Nowak, MSW, MS, Director, Advocacy and Advanced Stage Disease at Malecare. For more information about prostate cancer, visit http://malecare.org and http://advancedprostatecancer.net

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Host: Bruce Japsen Guest: Mark Frohlich, MD The cancer treatment Provenge, known as a "therapeutic vaccine," was approved by the Food and Drug Administration in April, 2010 as a novel way to attack prostate tumors. But this is more than the story of a new treatment. Host Bruce Japsen learns about the long path to FDA approval for this unique therapy that some see as a watershed development in oncology, from Dr. Mark Frohlich, senior vice president of clinical affairs and chief medical officer of Dendreon Corporation, the Seattle-based biotech company that manufactures Provenge.

Host: Bruce Japsen Guest: Mark Frohlich, MD The cancer treatment Provenge, known as a "therapeutic vaccine," was approved by the Food and Drug Administration in April, 2010 as a novel way to attack prostate tumors. But this is more than the story of a new treatment. Host Bruce Japsen learns about the long path to FDA approval for this unique therapy that some see as a watershed development in oncology, from Dr. Mark Frohlich, senior vice president of clinical affairs and chief medical officer of Dendreon Corporation, the Seattle-based biotech company that manufactures Provenge.

Flameouts are the norm for any company that dares to try to stimulate the body’s immune system to fight cancer cells. Cell Genesys, Genitope, Favrille, and Antigenics have been added to the long list of companies that have stumbled in this promising field that hasn’t yet produced a single FDA-approved therapy. One of the sector [...]Click here to play